StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for CCCC yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $3.57 | $3.56 | -0.28% | 2.3M |
| 05-18 | $3.53 | $3.22 | -8.78% | 2.3M |
| 05-19 | $3.16 | $3.11 | -1.58% | 1.9M |
| 05-20 | $3.16 | $3.28 | +3.80% | 1.6M |
| 05-21 | $3.23 | $3.52 | +9.15% | 2.1M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $6.15M | $35.95M | $24.93M | $13.70M |
Operating Income | $-27.79M | $-115.22M | $-92.08M | $-57.66M |
Net Income | $-25.13M | $-104.99M | $-84.51M | $-26.02M |
EPS (Diluted) | $-0.20 | $-1.27 | $-1.18 | $-0.74 |
Total Assets | $328.86M | $359.07M | $265.49M | $296.53M |
Total Liabilities | $94.61M | $102.49M | $111.08M | $122.46M |
Cash & Equivalents | $61.27M | $74.60M | $58.81M | $78.16M |
Free Cash Flow OCF − CapEx | $-30.01M | $-99.30M | $-77.14M | $-45.53M |
Shares Outstanding | 104.04M | 96.91M | 74.17M | 71.01M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.